Abecma News Today

The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.

Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.

The EMA's CHMP has recommended the approval of idecabtagene vicleucel in patients with multiple myeloma who received at least 2 prior therapies.

In the global trend of increasingly stringent emission norms, Euro 7, proposed for enforcement in light duty vehicles from July 2025, will set a new record. India has been following Europe for its emission regulations. In this exclusive interview, President, ECMA (an industry Body exclusively for emission control technology suppliers in India), and Head – Commercial, BASF Catalysts India, Harindranath Revanur, discusses with ETAuto’s Sumantra Bibhuti Barooah about BSVII, how easy or ...

Ethiopia has in the last two years opened up its telecommunications and banking sectors to participation of foreign firms.

Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from

By Colin Kellaher Bristol Myers Squibb Co. and 2seventy bio Inc. on Monday reported a trio of regulatory advances in their efforts to win approval for earlier use of their Abecma gene therapy... | April 17, 2023

Still ahead, more on the midterm elections including a closer look at the races that will determine control of the senate. which is a lot. so take care of that heart wiwith lipton. because sippin on unsweetened lipton can help support a healthy heart. lipton.. stop chuggin. start sippin. moderate to severe eczema still disrupts my skin. despite treatment it disrupts my skin with itch. it disrupts skin with rash. but now, i can disrupt ecma with rinvoq. rinvoq is not a steroid, topical,r injectio...

Mexicos president has blasted Abbott as “dishonest” and “sensationalist."

Bristol Myers Squibb has data showing that its multiple myeloma treatment Abecma beat the standard of care, preliminary Phase 3 results that could support moving the FDA-approved CAR T-cell therapy into an earlier line of treatment—ahead of a rival cell therapy. In other BMS cell therapy news, the pharma giant started an R&D alliance focused on inflammatory bowel disease.